- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03208374
Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling
This study will recruit approximately 5,000 patients with histologically confirmed cancer who have successfully completed MSK-IMPACT panel testing and collect information about tumor genetic results and patient exercise behavior history.
The purpose of the study is to create a registry to collect exercise behavior history in patients who had IMPACT genetic panel testing on protocol IRB #12-245 "Genomic Profiling in Cancer Patients", IRB #06-107 "Storage and Research Use of Human Biospecimens," or IRB #09-141 "Collection of Human Biological Specimens from Patients for Research Studies." The investigators want to find a way to create an exercise database. This database will collect information about tumor genetic results and patient exercise behavior history.
Study Overview
Status
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge (Consent Only)
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth (Consent Only)
-
Montvale, New Jersey, United States, 07645
- Memorial Sloan Kettering Bergen (Consent Only)
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack (Consent Only)
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester (Consent Only)
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, United States, 11553
- Memorial Sloan Kettering Nassau (Consent Only)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Cohort 1: IMPACT Cohort
Inclusion Criteria:
- Histologically-confirmed cancer.
- IMPACT testing with completed genomic profile completed within three years of initial recruitment approach
- Registered to Memorial Sloan Kettering Cancer Center protocol IRB# 12-245 and/or IRB #06-107 and/or IRB # 09-141
- ≥ 18 years of age
- ECOG Performance Status of 0 or 1
Exclusion Criteria:
- Unable to speak and read English
- Not willing to provide informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
MSK-IMPACT genetic panel testing
Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
|
Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g.
heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterize exercise participant behavior history via exercise survey
Time Frame: Up to 5 years
|
Participants who have undergone MSK-IMPACT panel testing will complete the exercise history survey.
The 10 minute survey only asks participants about their exercise history, both in period before their most recent diagnosis as well as their current exercise behavior.
|
Up to 5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jessica Scott, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 17-327
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Mayo ClinicRecruitingMultiple Myeloma | Myelodysplastic Syndrome | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Hematopoietic and Lymphoid System Neoplasm | Advanced Lung Carcinoma | Advanced Hepatocellular Carcinoma | Advanced Merkel Cell Carcinoma | Advanced Prostate Carcinoma | Advanced... and other conditionsUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncTerminatedMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
Sun Yat-sen UniversityTongji Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The... and other collaboratorsRecruitingUrothelial Carcinoma | Urothelial Carcinoma Recurrent | Advanced Urothelial CarcinomaChina
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Ireland, Mexico, South Korea, Colombia
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedBreast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Invasive Breast CarcinomaUnited States
-
University of Texas at AustinWashington University School of Medicine; Ohio State UniversityCompletedStage I Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | Ductal Carcinoma in Situ | Lobular Breast Carcinoma | Stage III Breast Cancer | Ductal Breast CarcinomaUnited States
Clinical Trials on Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire
-
Technical University of MunichMoving - ab jetzt gesund GmbHCompletedEndothelial Function (Reactive Hyperemia)Germany
-
Wayne State UniversityUniversity of MichiganCompleted
-
University of Alabama at BirminghamNational Cancer Institute (NCI); University of TennesseeActive, not recruitingKidney Cancer | Breast Cancer | Multiple Myeloma | Colorectal Cancer | Prostate Cancer | Non-Hodgkin Lymphoma | Endometrial Cancer | Thyroid Cancer | Ovary CancerUnited States
-
Karolinska InstitutetCompletedStroke | Transient Ischemic AttackSweden
-
University of MinnesotaNational Institute of Nursing Research (NINR)CompletedPhysical Activity | Exercise | Older Adults | Motivation | Accidental FallUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPancreatic Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Malignant Neoplasm | Recurrent Colorectal Carcinoma | Pancreatic Neuroendocrine Carcinoma | Malignant Head and Neck Neoplasm | Stage III Nasopharyngeal Carcinoma... and other conditionsUnited States
-
Thomas Jefferson UniversityCompletedHead and Neck Carcinoma | Lung Carcinoma | Oral Cavity Carcinoma | Paranasal Sinus Carcinoma | Stage III Laryngeal Cancer AJCC v8 | Stage IV Laryngeal Cancer AJCC v8 | Hypopharyngeal Carcinoma | Laryngeal Carcinoma | Stage IVA Laryngeal Cancer AJCC v8 | Stage IVB Laryngeal Cancer AJCC v8 | Stage IVC Laryngeal... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphatic System Neoplasm | Localized Malignant Solid NeoplasmUnited States
-
Thomas Jefferson UniversityCompletedAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast CarcinomaUnited States
-
Jasper A. SmitsNational Cancer Institute (NCI); University of Oklahoma; University of Houston; YMC...RecruitingNicotine DependenceUnited States